Chronic liver disease (CLD) caused by obesity, excessive alcohol consumption and 1 1 0 viral hepatitis represents a significant and increasing healthcare and socio-economic 1 1 1 burden worldwide. Non-alcoholic fatty liver disease (NAFLD) is now the commonest 1 1 2 form of CLD with a global prevalence of 25% (1). Despite advances in our 1 1 3 understanding of the pathogenic mechanisms that underlie NAFLD and liver fibrosis 1 1 4 in general, there are still no FDA-approved drug therapies. Important therapeutic 1 1 5 targets and promising drug candidates have been identified in preclinical models, 1 1 6 but reliable triage of efficacious therapies requires optimization and standardization 1 1 7 of drug development strategies and consensus on acceptable endpoints (2). In Current clinical trials of potential anti-NASH or antifibrotic drugs are anchored to 1 2 3 histopathological assessments of disease progression. However, liver biopsy is 1 2 4 hampered by invasiveness and sampling variability and is unpopular with patients. improved understanding and characterization of in vivo liver pathophysiology. It is a 1 2 7 versatile technique whereby structural and functional MRI can be performed in a 1 2 8 single multiparametric scan session, depicting changes associated with 1 2 9 inflammation, fibrosis, steatosis, siderosis, oxygenation, and tissue microstructure. Quantitative MRI parameters characterize these processes directly in the liver, LiverMultiScan TM can accurately quantify liver disease (5-7), may predict clinical 1 4 4 outcomes (8), and is now being adopted into clinical trial protocols as a surrogate 1 4 5 endpoint. We hypothesized that multiparametric MRI could be developed and 1 4 6 applied in experimental models of NASH and liver fibrosis using a small animal MR 1 4 7 scanner system, with potential future utility in preclinical drug development studies and spleen weights were recorded and liver tissue and blood were collected for 1 6 9 histological and biochemical analysis. One of the 12 week CCl 4 -treated animals was 1 7 0 euthanized prematurely due to poor health and excluded from analysis. The methionine and choline deficient (MCD) diet is a frequently used rodent model of Diets, New Jersey, USA) for 4 or 8 weeks (n=6 per group). Littermate control rats or 8 week treatment course under inhalational general anesthesia (1-2% isoflurane 1 8 0 9 in oxygen) without recovery. Body weight, liver and spleen weights were recorded 1 8 1 and liver tissue and blood were collected for histological and biochemical analysis. In a separate experiment, rats were fed an MCD diet for a total of 4 weeks. After 2 1 8 3 weeks, animals were randomized to treatment with either 100 mg/kg/day of cilostazol 1 8 4 (a phosphodiesterase type-3 inhibitor previously shown to reduce steatohepatitis in 1 8 5 experimental NAFLD models (9)) or vehicle by daily gavage from week 2 to week 4 1 8 6 (n=6 per group). Animals underwent MRI at baseline and after 4 weeks. All animals were continually monitored for vital signs and to maintain depth of 1 8 9 anesthesia. Respiration rate was monitored by detection of breathing motion by 1 9 0 compression of a respiratory sensor placed in contact with the abdomen and core Imaging studies were performed in anesthetized rats using a 7.0 Tesla preclinical 1 9 4 MRI scanner (Agilent Technologies, Santa Clara, CA, USA), with a 72 mm internal 1 9 5 diameter volume coil. At each timepoint, the following scans were run: two gradient- angle 20º), one scan with 4 in-phase echoes (1.01, 2.02, 3.03, 4.04 ms) and one 1 9 8 with 4 out-of-phase echoes (1.52, 2.53, 3.54, 4.55 ms), to measure fat using a 3-1 9 9 point Dixon method, and T2* using the 4 in-phase echoes. An adapted gradient echo 2 0 0 (fast low angle shot (FLASH)) Look-Locker sequence was used to measure T1 2 0 1 (acquired with 5 inversion times ranging from 270 to 5100 ms), 2 averages, flip angle 2 0 2 8º, echo train length 32). All scans were respiratory gated with a field of view (FOV) 2 0 3 60 mm × 60 mm, 2 mm thick single slice, 128 x 128 matrix. The pulse sequence was 2 0 4 based on previous work (10), but was adapted to use an inversion recovery module Data was exported in phase and magnitude format. T2* was determined using the in-2 1 1 phase gradient echo data (11) . Pixels in which the magnitude failed to exceed the 2 1 2 background noise by 2-fold (11) were excluded from the analysis. A combination of 2 1 3 the in-phase and out-of-phase gradient echo data were used to calculate proton 2 1 4 density fat and water maps using the extended 3-point Dixon approach described by 2 1 5
Glover and Schneider (12). The PDFF was calculated from the fat (F) and water (W) 2 1 6 maps as
T1 maps were calculated from the Look-Locker data as described previously (13). were not included in ROIs.
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To investigate the potential effect of parenchymal fat on hepatic T1, we also Serum alanine aminotransferase (ALT), was measured as described previously (14 City, UK). Within-run precision of these assays was calculated and expressed as 2 3 5 coefficient of variation (CV) < 4%, while intra-batch precision was CV < 5%. Liver tissue was fixed in 4% phosphate-buffered formaldehyde and embedded in fibrosis by picrosirus red, as described previously (16). Histology was assessed independently by an expert liver histopathologist, blinded to treatment allocation. disease, this is assessed by application of the NAFLD activity score (NAS). The ballooning 0-2) on hematoxylin and eosin (H&E) stained sections using the same Red O staining, assessed by a blinded assessor. Statistical analysis was performed using GraphPad Prism Version 6.0 (GraphPad mean±standard deviation (SD). To evaluate multiparametric MRI for the assessment of hepatic fibro-inflammatory 2 6 9 injury in a preclinical setting we used the rat CCl 4 model. Compared to OO controls, 2 7 0 animals receiving CCl 4 had higher serum transaminase levels and mild to moderate 2 7 1 liver inflammation after both 4 and 12 weeks CCl 4 ( Figure S1 ). Hepatic fibrogenic 2 7 2 activity increased progressively, with 12-fold greater α-SMA expression after 12 2 7 3 weeks in CCl 4 -treated rats compared to controls (P=0.006) ( Figure S1 ). Hepatic After 4 weeks, liver T1 was 1025±112 ms in CCl 4 rats compared to 984±138 ms in 2 7 8
OO controls (d=40.68, 95% CI (-141.7, 223.1), P=0.621) (Figure 1B,C) . There was a 2 7 9 significant difference in mean liver T1 in 12 week CCl 4 rats (1122±78 ms) compared 2 8 0 to controls (959±114 ms; d=162.7, 95% CI (11.92, 313.4), P=0.038) (Figure 1B,C) .
There was a strong positive correlation between liver T1 values and collagen To explore the influence of fat on hepatic T1, we used 1H-MRS to re-analyse two 2 8 6 distinct areas identified by different signal intensity on the T2-weighted structural 2 8 7
scan. Although one area had a much higher fat content, the T1 values were similar 2 8 8
( Figure S2 ). To explore the potential utility of multiparametric MRI as a non-invasive preclinical 2 9 2 diagnostic method for the assessment and staging of NAFLD and evaluation of anti-2 9 3 NASH treatments, we used the rat MCD diet model. Rats fed a MCD diet developed 2 9 4 florid micro-and macro-vesicular steatosis ( Figure S3 ). The proportionate area of Oil 2 9 5
Red O-stained fat in the liver was <0.5% in control rats, but in comparison was 2 9 6 grossly elevated after 4 weeks MCD diet (22.9±10.9%; P=0.004) and 8 weeks MCD diet (30.2±13.2%; P=0.002) ( Figure 2B ) with no significant difference between both 2 9 8 timepoints. Quantification of hepatic fat by MRI (mean of 3 ROIs) showed a highly significant (P=0.0005) and 2.09±1.16% (P<0.0001), respectively (Figure 2A,C) . The hepatic respectively) ( Figure 2D,E) . In contrast to animals receiving MCD diet, CCl 4 treated rats displayed a smaller vs. 0.26±0.19%, P=0.03) and 12 weeks (9.11±9.6% vs 0.30±0.13%, P=0.11) ( Figure   3 1 0 3B). Quantification of hepatic fat by MRI ( Figure 3A) showed an increase in PDFF 3 1 1 compared to controls after 4 weeks CCl 4 (3.86±1.83% vs 0.91±0.93%, P=0.016) and 3 1 2 12 weeks CCl 4 (3.58±0.33% vs. 1.85±0.87%, P=0.0044) ( Figure 3C ). Moreover, It had previously been shown that administration of cilostazol for 16 weeks reduced acid-defined (CDAA) diet or a high-fat high-calorie diet. We tested our MRI 3 1 9 methodology in rats that were fed MCD diet for 4 weeks plus treatment with performed similarly (Figure 4C,D) and, importantly, strong correlations were 3 2 6 1 5 observed between the histological assessment of steatotic inflammatory injury and 3 2 7 MRI measures (PDFF; r s =0.675, P=0.019) ( Figure 4E ).
2 8
Assessment of hepatic iron content in preclinical liver injury models 3 2 9
Hepatic iron may have a pathogenic role in NAFLD and, intriguingly, NAFLD itself with significant accumulation of iron in the liver (Figure S1 , Figure S3 ), but we did 3 3 4
observe variable effects on T2* in these models ( Figure 5A ). Consistent with the 3 3 5 lack of tissue iron staining, there was no change in liver R2* (1/T2*) in CCl 4 treated 3 3 6
rats compared with controls (P>0.05) ( Figure 5B ). However, we observed a 3 3 7 significant increase in R2* (1/ T2*) in MCD diet-treated rat livers compared with (213.6±22.5s -1 vs. 83.6±12.1s -1 , P<0.0001) ( Figure 5C ). Moreover, there was a 3 4 0 strong positive association between R2* and PDFF (r s =0.790, P<0.001) ( Figure 5D ), LiverMultiscan TM has shown promise as a clinical diagnostic tool and surrogate was to develop and apply this non-invasive, contrast-free multiparametric MRI 3 5 2 methodology in preclinical liver injury models that are commonly used in mechanistic 3 5 3
and drug evaluation studies.
3 5 4
Here we showed that our multiparametric liver MRI protocol was feasible at 7.0 3 5 5
Tesla in experimental rats and scanning was completed within a realistic time frame increasing duration of liver injury and were strongly correlated with histological 3 5 9
assessments of fibrosis and steatosis/steatotic inflammatory injury, respectively. Red O stained liver sections (21). The authors concluded that MRI was the preferred 3 6 9
method for fat quantification. The performance of LiverMultiscan TM in our 3 7 0 experimental rat models was broadly similar to that observed in patients with CLD 3 7 1 (r s =0.68, P<0.0001 for fibrosis; r s =0.89, P<0.001 for steatosis; r s =-0.69, P<0.0001 3 7 2 for siderosis) (5). Our findings indicate that multiparametric liver MRI could potentially refine the way 3 7 4
we currently approach testing of therapeutic candidates in preclinical models. Firstly, 3 7 5 multiparametric MRI could be used as a quantitative and objective method to stratify
